PHAT
Phathom Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.68
−1.05%Year over year
Reported trailing growth
- Revenue
- +86.8%
- EBITDA
- +90.3%
- EBIT
- +88.1%
- EPS
- +73.0%
- Free cash flow
- +90.8%
- Operating cash flow
- +90.8%
Forward estimates
Based on analyst estimates
- Revenue
- +59.0%
- EBITDA
- +595.2%
- EPS
- +121.0%
Three-year CAGR
- Revenue
- +1502.4%
- EBITDA
- +41.7%
- EBIT
- +42.3%
- Net income
- +33.8%
- EPS
- +42.7%
- Free cash flow
- +37.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026